Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Adults (aged 18 and over):
- People who have signed an informed consent form
- Adults aged 18 years or older
- People with a confirmed diagnosis of small cell lung cancer (new or returning), small cell carcinoma from an unknown or non-lung origin, or another type of neuroendocrine tumour — OR confirmed or suspected prostate cancer that has developed neuroendocrine features — OR a confirmed or suspected primary brain tumour — OR certain rare cancers including desmoplastic small round cell tumours, osteosarcoma, Ewing's sarcoma, rhabdomyosarcoma, Wilms tumour, hepatoblastoma, rhabdoid tumour, or neuroblastoma
- People with at least one tumour that is visible on a CT or MRI scan and measures at least 0.8 cm, OR a tumour detectable on specific nuclear medicine scans (such as FDG PET, PSMA PET, DOTATATE PET, or MIBG scans), OR new bone spread shown on MRI or bone scan — and these scans must have been done within the last 12 weeks
- People with a general health and activity level rated between 0 and 2 on a standard medical scale (meaning able to carry out at least some daily activities) (confirm with trial site)
- Women who could become pregnant must have a negative blood pregnancy test within 2 weeks of receiving the study imaging agent
- People who have stored tumour tissue available for a specific protein test (called DLL3 IHC), or whose doctor already plans to collect tumour tissue as part of their normal care
- Prostate cancer patients without stored tumour tissue available must be willing to have a biopsy guided by a PET/CT scan, if the trial team considers it appropriate
Children and teenagers (aged 4 and over):
- People who have signed an informed consent form
- Children and young people aged 4 years or older
- People diagnosed with high-risk neuroblastoma
- People with at least one tumour visible on CT or MRI measuring at least 0.8 cm, OR a tumour detectable on specific nuclear medicine scans, OR new bone spread shown on MRI or bone scan — all within the last 12 weeks
- People with a general health and activity level rated between 0 and 2 on a standard medical scale, and children under 16 must score at least 40 on a separate age-appropriate activity scale (confirm with trial site)
- Girls who could become pregnant must have a negative blood pregnancy test within 2 weeks of receiving the study imaging agent
Who may not be able to join:
Adults and children:
- People who have previously had a severe allergic (anaphylactic) reaction to humanised or human antibodies
- People who are currently pregnant or breastfeeding
- People with a psychiatric condition that would make it difficult to follow the study procedures
- People who are unable to have a PET scan because of weight restrictions on the scanning equipment
- People who would need general anaesthesia or sedation in order to tolerate a PET scan
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Mark P Dunphy, DO, Memorial Sloan Kettering Cancer Center
Phone: 212-639-8131
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Phase I: Radiation Dosimetry of 89Zr- DFO-SC16.56 PET/CT imaging in participants; Phase I: Safety of 89Zr- DFO-SC16.56 PET/CT imaging in cancer patients by evaluating toxicities; Phase II: Correlation between tumor uptake of 89Zr- DFO-SC16.56 with expression of DLL3
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.